![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 25-Mar-2013[ | E-mail |
Share ] Contact: Ellen Slingsby
eslingsby@lifespan.org
401-444-6421
Lifespan
Osteoarthritis is a painful, debilitating illness affecting more than 27 million people in the US
PROVIDENCE, R.I. Think new discoveries are the bee's knees? This one is even better -- this research out of Rhode Island Hospital is the mice's knees. Researchers have found that adding lubricin, a protein that our bodies naturally produce, to the fluid in our joints may reduce the risk of or even prevent osteoarthritis (OA). The findings, in a paper by Gregory D. Jay, M.D., Ph.D., of the department of emergency medicine, is published online in advance of print in the journal Proceedings of the National Academy of Sciences.
The discoveries were made in part by studying the knees of mice, which genetically lack lubricin, causing an aggressive arthritis in spite of high levels of hyaluronic acid in the synovial fluid. A lack of lubricin, resulting in higher friction, leads to cartilage cell death - even in the presence of high levels of hyaluronic acid, a viscous fluid that cushions the joints. This discovery appears to challenge the practice of injecting hyaluronic acid alone into a patient's joints.
"The lubricant is a protein, not hyaluronic acid, and currently, there are no disease-modifying treatments for osteoarthritis," Jay said. "Patients suffering from this degenerative joint disease either go through a total joint replacement, or are forced to live with pain every day. This discovery, however, supports that adding a lubricin replacement to the fluid in joints may in fact prevent osteoarthritis in those who have a genetic predisposition to the illness, or who have suffered significant trauma to the joints."
Jay added, "We are working to create a replacement for natural lubricin that we hope will significantly improve the treatment options, and ultimately prevention measures, for those with early osteoarthritis, or those with joint injuries."
OA, the most common form of arthritis, is a painful joint disease that can place severe limits on daily activity and quality of life. It causes pain, swelling and reduced motion in the joints, and while it can occur in any joint, it is most common in the hands, knees, hips or spine. The prevalence of OA increases beginning at age 45, according to the Centers for Disease Control and Prevention, and affects 27 million adults in the U.S. Risk factors include obesity, aging and injury/trauma to a joint.
"While many Baby Boomers are living longer, more active lives, obesity is a major problem in our country for many age groups," Jay said. "Both excessive weight, and injury to the joints can lead to osteoarthritis, which results in a more sedentary lifestyle. This discovery supports our ongoing efforts to produce a new therapy to protect cartilage among those with a transient loss of that protection, which places the cartilage at risk."
###
The study was funded by a grant from the National Institutes of Health (P20-GM104931, R01-AR049199, R01-AR050180, and R21-AR055937). Jay's principal affiliation is Rhode Island Hospital, a member hospital of the Lifespan health system in Rhode Island. He also has an academic appointment at The Warren Alpert Medical School of Brown University, department of emergency medicine and the Center for Biomedical Engineering and the School of Engineering, Brown University. Other researchers involved in the study are Kimberly A. Waller of Brown University; Ling X. Zhang of Rhode Island Hospital; Khaled A. Elsaid of the Massachusetts College of Pharmacy and Health Sciences; Braden C. Fleming of Rhode Island Hospital and Brown University; and Matthew L. Warman of Boston Children's Hospital.
Jay has authored patents on lubricin and PRG4. Patent numbers are USPTO#67443774, 6960562, and 7001881.
About Rhode Island Hospital
Founded in 1863, Rhode Island Hospital in Providence, R.I., is a private, not-for-profit hospital and is the principal teaching hospital of The Warren Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research. Last year, Rhode Island Hospital received more than $55 million in external research funding. It is also home to Hasbro Children's Hospital, the state's only facility dedicated to pediatric care. For more information on Rhode Island Hospital, visit http://www.rhodeislandhospital.org, follow us on Twitter @RIHospital or like us on Facebook http://www.facebook.com/rhodeislandhospitalpage.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 25-Mar-2013[ | E-mail |
Share ] Contact: Ellen Slingsby
eslingsby@lifespan.org
401-444-6421
Lifespan
Osteoarthritis is a painful, debilitating illness affecting more than 27 million people in the US
PROVIDENCE, R.I. Think new discoveries are the bee's knees? This one is even better -- this research out of Rhode Island Hospital is the mice's knees. Researchers have found that adding lubricin, a protein that our bodies naturally produce, to the fluid in our joints may reduce the risk of or even prevent osteoarthritis (OA). The findings, in a paper by Gregory D. Jay, M.D., Ph.D., of the department of emergency medicine, is published online in advance of print in the journal Proceedings of the National Academy of Sciences.
The discoveries were made in part by studying the knees of mice, which genetically lack lubricin, causing an aggressive arthritis in spite of high levels of hyaluronic acid in the synovial fluid. A lack of lubricin, resulting in higher friction, leads to cartilage cell death - even in the presence of high levels of hyaluronic acid, a viscous fluid that cushions the joints. This discovery appears to challenge the practice of injecting hyaluronic acid alone into a patient's joints.
"The lubricant is a protein, not hyaluronic acid, and currently, there are no disease-modifying treatments for osteoarthritis," Jay said. "Patients suffering from this degenerative joint disease either go through a total joint replacement, or are forced to live with pain every day. This discovery, however, supports that adding a lubricin replacement to the fluid in joints may in fact prevent osteoarthritis in those who have a genetic predisposition to the illness, or who have suffered significant trauma to the joints."
Jay added, "We are working to create a replacement for natural lubricin that we hope will significantly improve the treatment options, and ultimately prevention measures, for those with early osteoarthritis, or those with joint injuries."
OA, the most common form of arthritis, is a painful joint disease that can place severe limits on daily activity and quality of life. It causes pain, swelling and reduced motion in the joints, and while it can occur in any joint, it is most common in the hands, knees, hips or spine. The prevalence of OA increases beginning at age 45, according to the Centers for Disease Control and Prevention, and affects 27 million adults in the U.S. Risk factors include obesity, aging and injury/trauma to a joint.
"While many Baby Boomers are living longer, more active lives, obesity is a major problem in our country for many age groups," Jay said. "Both excessive weight, and injury to the joints can lead to osteoarthritis, which results in a more sedentary lifestyle. This discovery supports our ongoing efforts to produce a new therapy to protect cartilage among those with a transient loss of that protection, which places the cartilage at risk."
###
The study was funded by a grant from the National Institutes of Health (P20-GM104931, R01-AR049199, R01-AR050180, and R21-AR055937). Jay's principal affiliation is Rhode Island Hospital, a member hospital of the Lifespan health system in Rhode Island. He also has an academic appointment at The Warren Alpert Medical School of Brown University, department of emergency medicine and the Center for Biomedical Engineering and the School of Engineering, Brown University. Other researchers involved in the study are Kimberly A. Waller of Brown University; Ling X. Zhang of Rhode Island Hospital; Khaled A. Elsaid of the Massachusetts College of Pharmacy and Health Sciences; Braden C. Fleming of Rhode Island Hospital and Brown University; and Matthew L. Warman of Boston Children's Hospital.
Jay has authored patents on lubricin and PRG4. Patent numbers are USPTO#67443774, 6960562, and 7001881.
About Rhode Island Hospital
Founded in 1863, Rhode Island Hospital in Providence, R.I., is a private, not-for-profit hospital and is the principal teaching hospital of The Warren Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research. Last year, Rhode Island Hospital received more than $55 million in external research funding. It is also home to Hasbro Children's Hospital, the state's only facility dedicated to pediatric care. For more information on Rhode Island Hospital, visit http://www.rhodeislandhospital.org, follow us on Twitter @RIHospital or like us on Facebook http://www.facebook.com/rhodeislandhospitalpage.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-03/l-rhr032513.php
morgellons disease arik armstead sag awards red carpet torrey pines nhl all star game 2012 pollyanna samuel adams
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.